Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APSCVE:EMHNYSEARCA:SBMNASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.13+1.8%C$2.40C$1.02▼C$33.00C$48.66M1.365,110 shs17,164 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86MN/A3,024 shsN/ASVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.01N/AN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+1.80%-10.32%-52.92%-76.51%-96.23%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%0.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/AEMHEmerald Health Therapeutics 0.00N/AN/AN/ASBMProShares Short Basic Materials 0.00N/AN/AN/ASVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$0.71 per share1.60C($0.92) per shareN/AEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/ASVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$5.02N/A∞N/AN/A1,017.48%-136.29%N/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/AN/A0.00∞N/AN/AN/AN/AN/ASVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/A0.00%N/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ALatest SBM, APS, SVA, and EMH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025SVASinovac Biotech--$55.007/8/20255/23/20257/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41EMHEmerald Health Therapeutics35.452.972.61SBMProShares Short Basic MaterialsN/AN/AN/ASVASinovac BiotechN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences15.10%EMHEmerald Health TherapeuticsN/ASBMProShares Short Basic MaterialsN/ASVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%EMHEmerald Health TherapeuticsN/ASBMProShares Short Basic MaterialsN/ASVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3143.06 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableSBMProShares Short Basic MaterialsN/A40,000N/ANot OptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableSBM, APS, SVA, and EMH HeadlinesRecent News About These CompaniesSeeking a Cure for Sickly Corporate Governance at SinoVacJune 26 at 11:52 AM | finance.yahoo.comSINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder InterestsJune 24 at 4:59 PM | tmcnet.comSAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of ShareholdersJune 24 at 4:59 PM | theglobeandmail.comSinovac Clears Legal Hurdle In Control Battle, Moves Forward With $55 DividendJune 23, 2025 | msn.comPrime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special MeetingJune 21, 2025 | businesswire.comSINOVAC Board of Directors Prevails Against Advantech/Prime's New York LawsuitJune 20, 2025 | businesswire.comSINOVAC Board of Directors Files Definitive Proxy MaterialsJune 18, 2025 | businesswire.comSINOVAC Announces New Board MemberJune 18, 2025 | businesswire.comSINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All ShareholdersJune 17, 2025 | businesswire.comPrime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech’s Current BoardJune 17, 2025 | finance.yahoo.comHeng Ren urges Sinovac board to pay $55 cash dividend before July 8 voteJune 17, 2025 | finance.yahoo.comPrime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech's Current BoardJune 16, 2025 | businesswire.comSAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the BoardJune 16, 2025 | businesswire.comSINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid ShareholdersJune 16, 2025 | businesswire.comPrime Success Responds to Sinovac Biotech’s False and Misleading ClaimsJune 14, 2025 | bakersfield.comBPrime Success Responds to Sinovac Biotech's False and Misleading ClaimsJune 13, 2025 | businesswire.comSINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All ShareholdersJune 13, 2025 | standard-journal.comSSINOVAC's Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All ShareholdersJune 12, 2025 | businesswire.comVivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading ClaimsJune 11, 2025 | finance.yahoo.comVivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading ClaimsJune 11, 2025 | businesswire.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Overlooked Dividend Plays for Income in Volatile TimesBy Nathan Reiff | May 31, 2025View 3 Overlooked Dividend Plays for Income in Volatile TimesSBM, APS, SVA, and EMH Company DescriptionsAptose Biosciences TSE:APSC$1.13 +0.02 (+1.80%) As of 06/26/2025 03:59 PM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.ProShares Short Basic Materials NYSEARCA:SBM$46.38 0.00 (0.00%) As of 05/12/2023ProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
